Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.

Sanseviero E, O'Brien EM, Karras JR, Shabaneh TB, Aksoy BA, Xu W, Zheng C, Yin X, Xu X, Karakousis GC, Amaravadi RK, Nam B, Turk MJ, Hammerbacher J, Rubinstein MP, Schuchter LM, Mitchell TC, Liu Q, Stone EL.

Cancer Immunol Res. 2019 Aug;7(8):1371-1380. doi: 10.1158/2326-6066.CIR-18-0386. Epub 2019 Jun 25.

PMID:
31239316
2.

Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity.

Molodtsov A, Turk MJ.

Front Immunol. 2018 Nov 29;9:2810. doi: 10.3389/fimmu.2018.02810. eCollection 2018. Review.

3.

A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis.

Zhao Y, Schaafsma E, Gorlov IP, Hernando E, Thomas NE, Shen R, Turk MJ, Berwick M, Amos CI, Cheng C.

Mol Cancer Res. 2019 Jan;17(1):109-119. doi: 10.1158/1541-7786.MCR-18-0173. Epub 2018 Aug 31.

PMID:
30171176
4.

Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis.

Shabaneh TB, Molodtsov AK, Steinberg SM, Zhang P, Torres GM, Mohamed GA, Boni A, Curiel TJ, Angeles CV, Turk MJ.

Cancer Res. 2018 Sep 1;78(17):5038-5049. doi: 10.1158/0008-5472.CAN-18-0365. Epub 2018 Jul 19.

5.

VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.

Kuklinski LF, Yan S, Li Z, Fisher JL, Cheng C, Noelle RJ, Angeles CV, Turk MJ, Ernstoff MS.

Cancer Immunol Immunother. 2018 Jul;67(7):1113-1121. doi: 10.1007/s00262-018-2169-1. Epub 2018 May 8.

PMID:
29737375
6.

Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.

Padrón Á, Hurez V, Gupta HB, Clark CA, Pandeswara SL, Yuan B, Svatek RS, Turk MJ, Drerup JM, Li R, Curiel TJ.

Exp Gerontol. 2018 May;105:146-154. doi: 10.1016/j.exger.2017.12.025. Epub 2018 Jan 8.

PMID:
29326088
7.

Challenges faced when identifying patients for combination immunotherapy.

Ernstoff MS, Gandhi S, Pandey M, Puzanov I, Grivas P, Montero A, Velcheti V, Turk MJ, Diaz-Montero CM, Lewis LD, Morrison C.

Future Oncol. 2017 Aug;13(18):1607-1618. doi: 10.2217/fon-2017-0218. Epub 2017 Aug 24. Review.

PMID:
28835114
8.

Resident memory T cells in the skin mediate durable immunity to melanoma.

Malik BT, Byrne KT, Vella JL, Zhang P, Shabaneh TB, Steinberg SM, Molodtsov AK, Bowers JS, Angeles CV, Paulos CM, Huang YH, Turk MJ.

Sci Immunol. 2017 Apr 14;2(10). pii: eaam6346. doi: 10.1126/sciimmunol.aam6346.

9.

Crops In Silico: Generating Virtual Crops Using an Integrative and Multi-scale Modeling Platform.

Marshall-Colon A, Long SP, Allen DK, Allen G, Beard DA, Benes B, von Caemmerer S, Christensen AJ, Cox DJ, Hart JC, Hirst PM, Kannan K, Katz DS, Lynch JP, Millar AJ, Panneerselvam B, Price ND, Prusinkiewicz P, Raila D, Shekar RG, Shrivastava S, Shukla D, Srinivasan V, Stitt M, Turk MJ, Voit EO, Wang Y, Yin X, Zhu XG.

Front Plant Sci. 2017 May 15;8:786. doi: 10.3389/fpls.2017.00786. eCollection 2017.

10.

Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.

Steinberg SM, Shabaneh TB, Zhang P, Martyanov V, Li Z, Malik BT, Wood TA, Boni A, Molodtsov A, Angeles CV, Curiel TJ, Whitfield ML, Turk MJ.

Cancer Res. 2017 Apr 1;77(7):1599-1610. doi: 10.1158/0008-5472.CAN-16-1755. Epub 2017 Feb 15.

11.

Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.

Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, Liu Y, Turk MJ, Thedieck K, Hurez V, Li R, Vadlamudi R, Curiel TJ.

Cancer Res. 2016 Dec 1;76(23):6964-6974. Epub 2016 Sep 26. Erratum in: Cancer Res. 2017 May 15;77(10 ):2770.

12.

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.

Whipple CA, Boni A, Fisher JL, Hampton TH, Tsongalis GJ, Mellinger DL, Yan S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS.

Melanoma Res. 2016 Jun;26(3):223-35. doi: 10.1097/CMR.0000000000000244.

PMID:
26974965
13.

Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.

Clancy-Thompson E, Perekslis TJ, Croteau W, Alexander MP, Chabanet TB, Turk MJ, Huang YH, Mullins DW.

Cancer Immunol Res. 2015 Aug;3(8):956-67. doi: 10.1158/2326-6066.CIR-15-0015. Epub 2015 Jun 5.

14.

BRAF-inhibition and tumor immune suppression.

Steinberg SM, Turk MJ.

Oncoimmunology. 2015 Mar 6;4(2):e988039. eCollection 2015 Feb. Review.

15.

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ.

Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2.

16.

Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors.

Toraya-Brown S, Sheen MR, Zhang P, Chen L, Baird JR, Demidenko E, Turk MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S.

Nanomedicine. 2014 Aug;10(6):1273-1285. doi: 10.1016/j.nano.2014.01.011. Epub 2014 Feb 22.

17.

Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.

Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE.

Pigment Cell Melanoma Res. 2014 May;27(3):495-501. doi: 10.1111/pcmr.12220. Epub 2014 Mar 6. No abstract available.

18.

Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

Byrne KT, Zhang P, Steinberg SM, Turk MJ.

J Immunol. 2014 Feb 15;192(4):1433-9. doi: 10.4049/jimmunol.1302139. Epub 2014 Jan 8.

19.

Tumor endothelial marker imaging in melanomas using dual-tracer fluorescence molecular imaging.

Tichauer KM, Deharvengt SJ, Samkoe KS, Gunn JR, Bosenberg MW, Turk MJ, Hasan T, Stan RV, Pogue BW.

Mol Imaging Biol. 2014 Jun;16(3):372-82. doi: 10.1007/s11307-013-0692-1. Epub 2013 Nov 12.

20.

Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.

Black CC, Turk MJ, Dragnev K, Rigas JR.

Lung. 2013 Jun;191(3):265-70. doi: 10.1007/s00408-013-9455-7. Epub 2013 Mar 15.

PMID:
23494387
21.

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S.

J Immunol. 2013 Jan 1;190(1):469-78. doi: 10.4049/jimmunol.1201209. Epub 2012 Dec 7.

22.

Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy.

Toraya-Brown S, Sheen MR, Baird JR, Barry S, Demidenko E, Turk MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S.

Integr Biol (Camb). 2013 Jan;5(1):159-71. doi: 10.1039/c2ib20180a.

23.

A retinoic acid--rich tumor microenvironment provides clonal survival cues for tumor-specific CD8(+) T cells.

Guo Y, Pino-Lagos K, Ahonen CA, Bennett KA, Wang J, Napoli JL, Blomhoff R, Sockanathan S, Chandraratna RA, Dmitrovsky E, Turk MJ, Noelle RJ.

Cancer Res. 2012 Oct 15;72(20):5230-9. doi: 10.1158/0008-5472.CAN-12-1727. Epub 2012 Aug 17.

24.

Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help.

Côté AL, Byrne KT, Steinberg SM, Zhang P, Turk MJ.

PLoS One. 2011;6(10):e26491. doi: 10.1371/journal.pone.0026491. Epub 2011 Oct 26.

25.

New perspectives on the role of vitiligo in immune responses to melanoma.

Byrne KT, Turk MJ.

Oncotarget. 2011 Sep;2(9):684-94. Review.

26.

Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.

Byrne KT, Côté AL, Zhang P, Steinberg SM, Guo Y, Allie R, Zhang W, Ernstoff MS, Usherwood EJ, Turk MJ.

J Clin Invest. 2011 May;121(5):1797-809. doi: 10.1172/JCI44849. Epub 2011 Apr 11.

27.

Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.

Côté AL, Zhang P, O'Sullivan JA, Jacobs VL, Clemis CR, Sakaguchi S, Guevara-Patiño JA, Turk MJ.

J Immunol. 2011 Jan 1;186(1):275-83. doi: 10.4049/jimmunol.1001308. Epub 2010 Nov 24.

28.

IL-35-mediated induction of a potent regulatory T cell population.

Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ, Vignali DA.

Nat Immunol. 2010 Dec;11(12):1093-101. doi: 10.1038/ni.1952. Epub 2010 Oct 17.

29.

Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.

Gunturu KS, Meehan KR, Mackenzie TA, Crocenzi TS, McDermott D, Usherwood EJ, Margolin KA, Crosby NA, Atkins MB, Turk MJ, Ahonen C, Fuse S, Clark JI, Fisher JL, Noelle RJ, Ernstoff MS.

J Clin Oncol. 2010 Mar 1;28(7):1196-202. doi: 10.1200/JCO.2009.24.8153. Epub 2010 Feb 1.

30.

A persistent virus vector confers superior anti-tumor immunity, compared with a non-persistent vector.

Zhang W, Zhang T, Turk MJ, Usherwood EJ.

Cancer Immunol Immunother. 2010 May;59(5):707-13. doi: 10.1007/s00262-009-0790-8.

31.

CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.

Nesbeth Y, Scarlett U, Cubillos-Ruiz J, Martinez D, Engle X, Turk MJ, Conejo-Garcia JR.

Cancer Res. 2009 Aug 1;69(15):6331-8. doi: 10.1158/0008-5472.CAN-08-4329. Epub 2009 Jul 14.

32.

The formation of Population III binaries from cosmological initial conditions.

Turk MJ, Abel T, O'Shea B.

Science. 2009 Jul 31;325(5940):601-5. doi: 10.1126/science.1173540. Epub 2009 Jul 9.

33.

Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.

Huarte E, Fisher J, Turk MJ, Mellinger D, Foster C, Wolf B, Meehan KR, Fadul CE, Ernstoff MS.

Cancer Lett. 2009 Nov 18;285(1):80-8. doi: 10.1016/j.canlet.2009.05.003. Epub 2009 Jun 6.

34.

Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression.

Bak SP, Alonso A, Turk MJ, Berwin B.

Mol Immunol. 2008 Dec;46(2):258-68. doi: 10.1016/j.molimm.2008.08.266. Epub 2008 Sep 27.

35.

Tumor-specific T-cell memory: clearing the regulatory T-cell hurdle.

Côté AL, Usherwood EJ, Turk MJ.

Cancer Res. 2008 Mar 15;68(6):1614-7. doi: 10.1158/0008-5472.CAN-07-6012. Review.

36.

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, Gorham JD, Kedl RM, Usherwood EJ, Noelle RJ.

Blood. 2008 Mar 15;111(6):3116-25. doi: 10.1182/blood-2007-09-114371. Epub 2008 Jan 17.

37.

Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor.

Zhang P, Côté AL, de Vries VC, Usherwood EJ, Turk MJ.

Cancer Res. 2007 Jul 1;67(13):6468-76.

38.

Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains.

Ferrone CR, Perales MA, Goldberg SM, Somberg CJ, Hirschhorn-Cymerman D, Gregor PD, Turk MJ, Ramirez-Montagut T, Gold JS, Houghton AN, Wolchok JD.

Clin Cancer Res. 2006 Sep 15;12(18):5511-9.

39.

Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.

Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, Goldberg SM, Wolchok JD, Houghton AN.

Adv Immunol. 2006;90:215-41. Review.

PMID:
16730265
40.

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN.

Cancer Res. 2006 May 1;66(9):4904-12.

41.

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity.

Guevara-Patiño JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, Cohen AD, Merghoub T, Wolchok JD, Houghton AN.

J Clin Invest. 2006 May;116(5):1382-90. Epub 2006 Apr 13.

42.

Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.

Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP.

Anal Biochem. 2005 Mar 15;338(2):284-93.

PMID:
15745749
43.

Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN.

J Exp Med. 2004 Sep 20;200(6):771-82. Erratum in: J Exp Med. 2005 Jan 3;201(1):159.

44.

Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery.

Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS.

Mol Pharmacol. 2004 Dec;66(6):1406-14. Epub 2004 Sep 15.

PMID:
15371560
45.

Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma.

Turk MJ, Waters DJ, Low PS.

Cancer Lett. 2004 Sep 30;213(2):165-72.

PMID:
15327831
46.

Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis.

Paulos CM, Turk MJ, Breur GJ, Low PS.

Adv Drug Deliv Rev. 2004 Apr 29;56(8):1205-17. Review.

PMID:
15094216
47.

Immunity to cancer through immune recognition of altered self: studies with melanoma.

Guevara-Patiño JA, Turk MJ, Wolchok JD, Houghton AN.

Adv Cancer Res. 2003;90:157-77. Review.

PMID:
14710950
48.

GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines.

Perales MA, Fantuzzi G, Goldberg SM, Turk MJ, Mortazavi F, Busam K, Houghton AN, Dinarello CA, Wolchok JD.

Cytokines Cell Mol Ther. 2002;7(3):125-33.

PMID:
12850812
49.

Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.

Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN.

Oncogene. 2003 May 19;22(20):3180-7. Review.

PMID:
12789294
50.

Multiple pathways to tumor immunity and concomitant autoimmunity.

Turk MJ, Wolchok JD, Guevara-Patino JA, Goldberg SM, Houghton AN.

Immunol Rev. 2002 Oct;188:122-35. Review.

PMID:
12445286

Supplemental Content

Support Center